论文部分内容阅读
目的：评价阿德福韦联合贞芪扶正胶囊治疗慢性乙型肝炎(CHB)的疗效。方法按就诊的先后次序，将60例CHB患者在保肝治疗基础上，被随机分为治疗组和对照组，治疗组30例，对照组30例，治疗组联用贞芪扶正胶囊和阿德福韦，对照组为单用阿德福韦，两组疗程均为48周。观察用药前及用药后48周时的肝生化指标、HBVDNA载量、血清HBeAg阴转率及HbeAg血清转换率等变化。结果治疗后2组肝生化指标、HBV DNA载量均有不同程度的好转。治疗组ALT、AST的下降较对照组差异有统计学意义(P<0．05)。治疗后48周，治疗组HBVDNA阴转率为53.3％，明显高于对照组(33.3％)。血清HBeAg阴转率：治疗48周时，治疗组56.7％，对照组30.0％，两组差异均有统计学意义(P<0．05)。结论阿德福韦联合贞芪扶正胶囊治疗CHB，在恢复肝功能、降低HBVDNA载量及血清HBeAg阴转率方面均优于单用阿德福韦。“,”Objective To investigate the effect of adefovir single and it combined Zhenqifuzheng capsule in the treatment of chronic hepatitis B(CHB).Methods 60 patients of CHB on the basis of treating liver were divided into two groups randomly.There were 30 patienls in treatment group and30 patients in control group.The treatment group used Zhenqifuzheng capsule combined with adefovir,and the controlgroup used adefovir only,both treatment course were 48 weeks. The biochemical and HBVDNA load were determined by immunoassay after treatment with drugs for 48 weeks.Results The biochemical in liver was improved after treatment in two groups.The ALT and AST decreased in trial group more than the control group(P<0.05).The negative response rate of HBV DNA Was 53.3%.33.3%in trial group and control group.HBeAg seroeonvertion rate:after 48 weeks,the rate in treatment group(56.7%) was higher than that in conlrol group(30.0%). there was a statistical difference between the two group(P<0.05).Conclusion Adefovir combined with Zhenqifuzheng capsule for CHB is superior to adefovir alone in biochemical in liver,reducing the HBVDNA load and enhancing HBeAg seroconvertion rate.